Sukhtian Ghiath M. — SEC Form 4 filings
SEC reporting owner CIK 1717441. 6 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 6 filings on record, filed 2024-03-20 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 11,064,961 shares, $7,499,999 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 8,539,709 shares @ $0.59 ($5,000,000) in Outlook Therapeutics, Inc., filed 2026-06-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | Director, 10% owner | 6 | 2 legs · 11,064,961 sh · $7,499,999 | — | 17 |
Form 4 filings — Sukhtian Ghiath M.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Purchase (P): 2,525,252 @ $0.99 · Purchase (P): 2,525,252 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Purchase (P): 8,539,709 @ $0.59 · Code (H): 3,458,571 (derivative) · Purchase (P): 3,458,571 (derivative) · Code (H): 3,458,571 (derivative) · Purchase (P): 3,458,571 (derivative) · Code (H): 8,571,428 (derivative) · +1 more | EDGAR |
| 2025-05-28 | 4 | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Grant/award (A): 4,285,714 @ $1.40 · Grant/award (A): 8,571,428 (derivative) | EDGAR |
| 2025-03-12 | 4/A | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Option exercise (M): 3,458,571 @ $2.51 | EDGAR |
| 2025-01-22 | 4 | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Disposition to issuer (D): 3,458,571 (derivative) · Grant/award (A): 3,458,571 (derivative) · Option exercise (M): 3,458,571 (derivative) · Grant/award (A): 3,458,571 (derivative) · Grant/award (A): 3,458,571 (derivative) | EDGAR |
| 2024-03-20 | 4 | Outlook Therapeutics, Inc. (OTLK) jointly with GMS Ventures & Investments | Grant/award (A): 2,305,714 · Grant/award (A): 3,458,571 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1717441 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →